Literature DB >> 22193155

Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI.

Rui Vasco Simões1, Sandra Ortega-Martorell, Teresa Delgado-Goñi, Yann Le Fur, Martí Pumarola, Ana Paula Candiota, Juana Martín, Radka Stoyanova, Patrick J Cozzone, Margarida Julià-Sapé, Carles Arús.   

Abstract

Classifiers based on statistical pattern recognition analysis of MRSI data are becoming important tools for the non-invasive diagnosis of human brain tumors. Here we investigate the potential interest of perturbation-enhanced MRSI (PE-MRSI), in this case acute hyperglycemia, for improving the discrimination between mouse brain MRS patterns of glioblastoma multiforme (GBM), oligodendroglioma (ODG), and non-tumor brain parenchyma (NT). Six GBM-bearing mice and three ODG-bearing mice were scanned at 7 Tesla by PRESS-MRSI with 12 and 136 ms echo-time, during euglycemia (Eug) and also during induced acute hyperglycemia (Hyp), generating altogether four datasets per animal (echo time + glycemic condition): 12Eug, 136Eug, 12Hyp, and 136Hyp. For classifier development all spectral vectors (spv) selected from the MRSI matrix were unit length normalized (UL2) and used either as a training set (76 GBM spv, four mice; 70 ODG spv, two mice; 54 NT spv) or as an independent testing set (61 GBM spv, two mice; 31 ODG, one mouse; 23 NT spv). All Fisher's LDA classifiers obtained were evaluated as far as their descriptive performance-correctly classified cases of the training set (bootstrapping)-and predictive accuracy-balanced error rate of independent testing set classification. MRSI-based classifiers at 12Hyp were consistently more efficient in separating GBM, ODG, and NT regions, with overall accuracies always >80% and up to 95-96%; remaining classifiers were within the 48-85% range. This was also confirmed by user-independent selection of training and testing sets, using leave-one-out (LOO). This highlights the potential interest of perturbation-enhanced MRSI protocols for improving the non-invasive characterization of preclinical brain tumors. This journal is © The Royal Society of Chemistry 2012

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193155     DOI: 10.1039/c2ib00079b

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  4 in total

1.  Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.

Authors:  Magdalena Ciezka; Milena Acosta; Cristina Herranz; Josep M Canals; Martí Pumarola; Ana Paula Candiota; Carles Arús
Journal:  J Neurooncol       Date:  2016-06-21       Impact factor: 4.130

2.  In Vivo Detection of Perinatal Brain Metabolite Changes in a Rabbit Model of Intrauterine Growth Restriction (IUGR).

Authors:  Rui V Simões; Emma Muñoz-Moreno; Rodrigo J Carbajo; Anna González-Tendero; Miriam Illa; Magdalena Sanz-Cortés; Antonio Pineda-Lucena; Eduard Gratacós
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

3.  Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Authors:  Nuria Arias-Ramos; Laura Ferrer-Font; Silvia Lope-Piedrafita; Victor Mocioiu; Margarida Julià-Sapé; Martí Pumarola; Carles Arús; Ana Paula Candiota
Journal:  Metabolites       Date:  2017-05-18

4.  Convex non-negative matrix factorization for brain tumor delimitation from MRSI data.

Authors:  Sandra Ortega-Martorell; Paulo J G Lisboa; Alfredo Vellido; Rui V Simões; Martí Pumarola; Margarida Julià-Sapé; Carles Arús
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.